Regeneron Reports Second Quarter 2026 Financial and Operating Results
REGENERON PHARMACEUTICALS, INC. (REGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2026 Financial and Operating Results • Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 • Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0
How this was made
The 30-second read
Why it matters
Key tradable inputs include quarterly revenue and EPS figures, product net sales growth across Dupixent, Libtayo, and EYLEA HD, and a stated repayment of the Sanofi Development Balance that is expected to drive higher collaboration profits beginning in Q3.
Market read
Fresh quarterly earnings and operating metrics plus a specific collaboration-profit timing catalyst (Sanofi repayment) make this a meaningful update for near-term valuation and positioning.
What to watch
Sanofi collaboration revenue rose 51% but Bayer collaboration revenue fell 33%, so investors may scrutinize sustainability of collaboration mix and margins beyond the Sanofi repayment step-up.
Second quarter 2026 revenue rose 17% to $4,291 million, supported by Sanofi collaboration revenue and growth in EYLEA HD and Libtayo, while GAAP net income declined 7% to $1,297 million.
Revenue and non-GAAP diluted EPS increased by double digits, driven by higher Sanofi collaboration revenue and strong EYLEA HD and Libtayo sales. GAAP net income declined, gross margin contracted, and full-year gross-margin guidance was lowered.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $4.29B | – | 17% |
| Total net product salesGAAP | $1.64B | – | 1% |
| Sanofi collaboration revenueGAAP | $2.17B | – | 51% |
| Bayer collaboration revenueGAAP | $276M | – | (33%) |
| Other collaboration revenueGAAP | $6M | – | – |
| Other revenueGAAP | $193M | – | 5% |
| Company's share of profits from the commercialization of antibodiesother | $2.03B | – | – |
| GAAP net incomeGAAP | $1.30B | – | (7%) |
| GAAP net income per share - dilutedGAAP | $12.23 | – | (5%) |
| Non-GAAP net incomenon-GAAP | $1.54B | – | 8% |
| Non-GAAP net income per share - dilutednon-GAAP | $14.29 | – | 11% |
| Research and development (R&D)GAAP | $1.63B | – | 15% |
| Research and development (R&D)non-GAAP | $1.5B | – | 17% |
| Acquired in-process research and development (IPR&D)GAAP | $127M | – | – |
| Selling, general, and administrative (SG&A)GAAP | $662M | – | 4% |
| Selling, general, and administrative (SG&A)non-GAAP | $574M | – | 6% |
| Cost of goods sold (COGS)GAAP | $361M | – | 31% |
| Cost of goods sold (COGS)non-GAAP | $221M | – | — % |
| Gross margin on net product salesGAAP | 78% | – | – |
| Gross margin on net product salesnon-GAAP | 87% | – | – |
| Cost of collaboration and contract manufacturing (COCM)GAAP | $216M | – | (15%) |
| GAAP effective tax rate (ETR)GAAP | 15.1% | – | – |
| Non-GAAP effective tax rate (ETR)non-GAAP | 15.5% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| EYLEA HD - U.S.Higher sales volumes driven by increased demand, partly offset by a lower net selling price. | $596M | – | 52% |
| EYLEA - U.S.Lower sales volumes driven by decreased demand, continued competitive pressures, continued transition of patients to EYLEA HD, and a lower net selling price. | $412M | – | (45%) |
| Total EYLEA HD and EYLEA - U.S.EYLEA HD growth was more than offset by lower EYLEA sales. | $1.01B | – | (12%) |
| Libtayo - U.S.Global Libtayo sales increased primarily due to higher sales volumes driven by increased demand. | $343M | – | 38% |
| Libtayo - ROWGlobal Libtayo sales increased primarily due to higher sales volumes driven by increased demand. | $146M | – | 13% |
| Total Libtayo - GlobalHigher sales volumes driven by increased demand. | $489M | – | 30% |
| Praluent - U.S.Not discussed. | $75M | – | 14% |
| Evkeeza - U.S.Not discussed. | $53M | – | 29% |
| Lynozyfic - GlobalNot discussed. | $17M | – | – |
| SanofiHigher share of profits from commercialization of antibodies, primarily associated with an increase in Dupixent sales. | $2.17B | – | 51% |
| BayerNot discussed. | $276M | – | (33%) |
| Other revenueNot discussed. | $193M | – | 5% |
Full year 2026 outlook
- Gross marginGAAP gross margin on net product sales: 78%–79%; Non-GAAP gross margin on net product sales: 84%–85%
- Operating expensesGAAP R&D: $6.500–$6.635 billion; Non-GAAP R&D: $5.950–$6.050 billion; GAAP SG&A: $2.830–$2.960 billion; Non-GAAP SG&A: $2.500–$2.600 billion
- NoteGAAP COCM: $985 million–$1.035 billion
Capital returns
- During the three months ended June 30, 2026, the Company repurchased $1.2 billion of its common stock.
- During the six months ended June 30, 2026, the Company repurchased $2.0 billion of its common stock.
- As of June 30, 2026, $2.5 billion remained available for share repurchases under the Company's share repurchase programs.
- In July 2026, the board declared a cash dividend of $0.94 per share, payable on August 31, 2026 to shareholders of record as of August 18, 2026.
- The Company said nearly $3.0 billion was deployed in the first half of the year to share repurchases, dividends, capital expenditures, and business development.
What drove it
- Total revenue growth reflected a 51% increase in Sanofi collaboration revenue, primarily associated with increased Dupixent sales.
- U.S. EYLEA HD sales grew 52% through higher sales volumes driven by increased demand, partly offset by a lower net selling price.
- Global Libtayo sales grew 30%, primarily due to higher sales volumes driven by increased demand.
- R&D expense growth was driven by the Company's mid- and late-stage clinical pipeline.
- The Company reported approximately 50 product candidates in clinical development.
Concerns
- U.S. EYLEA sales declined 45% amid lower demand, competitive pressures, patient transitions to EYLEA HD, and a lower net selling price.
- GAAP gross margin on net product sales fell to 78% from 83% due primarily to unabsorbed manufacturing costs following the temporary interruption of bulk manufacturing production at Limerick, Ireland.
- GAAP net income declined 7% and GAAP diluted EPS declined 5%, while acquired IPR&D expense was $127 million.
- The Phase 3 fianlimab plus cemiplimab melanoma trial did not reach statistical significance for its primary progression-free-survival endpoint compared to pembrolizumab monotherapy.
- GAAP and non-GAAP effective tax rates increased to 15.1% and 15.5%, respectively.
What to watch
- The step-up in collaboration profits beginning in the third quarter of 2026 following repayment of the Sanofi Development Balance.
- Whether bulk manufacturing production at the Limerick, Ireland facility remains at normal levels following its return to normal levels as of the end of the second quarter of 2026.
- The FDA target action date in November 2026 for cemdisiran in adult patients with generalized myasthenia gravis.
- Execution of the Phase 2 registrational-intent portion of the LINKER-AL2 trial for Lynozyfic in systemic amyloid light chain amyloidosis.
- Progress of the Phase 3 peripheral artery disease study for cenvacibart and amrecibart.
Balance sheet and cash flow
- The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026.
- The Sanofi Development Balance will no longer reduce Sanofi collaboration revenue beginning in the third quarter of 2026.
Analysis
Regeneron reported second-quarter 2026 total revenues of $4,291 million, up 17% from $3,676 million. The primary contributor was Sanofi collaboration revenue, which increased 51% to $2,174 million. The Company attributed this to a higher share of commercialization profits from antibodies, primarily associated with higher Dupixent sales. Dupixent global net sales, recorded by Sanofi, increased 38% to $6.0 billion.
Product sales were broadly flat, with total net product sales of $1,642 million versus $1,631 million. U.S. EYLEA HD sales increased 52% to $596 million on demand-led volume growth, but U.S. EYLEA sales declined 45% to $412 million amid competitive pressure, lower demand, patient migration to EYLEA HD, and lower net selling prices. Combined U.S. EYLEA HD and EYLEA sales declined 12% to $1,008 million. Libtayo was a key positive, with global sales up 30% to $489 million, primarily due to higher demand-driven sales volumes.
Profitability was mixed. Non-GAAP net income increased 8% to $1,543 million and non-GAAP diluted EPS increased 11% to $14.29. GAAP net income declined 7% to $1,297 million and GAAP diluted EPS fell 5% to $12.23. The period included $127 million of acquired IPR&D expense, while GAAP gross margin on net product sales declined to 78% from 83% because of unabsorbed manufacturing costs related to the temporary bulk-manufacturing interruption in Limerick, Ireland. The Company said production returned to normal levels by quarter end and product availability was not affected.
The Company fully repaid the Sanofi Development Balance as of the end of the second quarter. Regeneron said the obligation will no longer reduce Sanofi collaboration revenue beginning in the third quarter, making the collaboration-profit trajectory a central near-term item. Capital returns included $1.2 billion in common-stock repurchases during the quarter, with $2.5 billion remaining under repurchase programs as of June 30, 2026, alongside a declared $0.94 per-share cash dividend.
Full-year guidance shown in the filing indicates lower gross-margin ranges than the prior ranges displayed in the guidance table, with GAAP gross margin on net product sales at 78%–79% and non-GAAP gross margin at 84%–85%. The filing also shows updated ranges for R&D, SG&A, and GAAP COCM. Pipeline attention centers on the November 2026 FDA target action date for cemdisiran in generalized myasthenia gravis, while the fianlimab melanoma trial outcome was a setback because it did not achieve its primary endpoint.
Management, verbatim
Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline.
Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer
Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures.
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported revenue, product sales, collaboration revenue, earnings, EPS, operating expenses, gross margin, and tax rates were not reported.
- GAAP and non-GAAP operating income were not reported in the provided filing text.
- Operating cash flow, free cash flow, cash balance, marketable securities balance, total debt, and net debt were not reported in the provided filing text.
- Full-year 2026 revenue guidance and tax-rate guidance were not reported in the provided filing text.
- The provided filing text is truncated in the 2026 guidance table, so the updated non-GAAP COCM range and any following guidance items are not available.
- A previous earnings release outlook section was not provided, so actual results cannot be assessed against prior guidance.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 press release covering Regeneron’s Q2 2026 financial and operating results plus pipeline and corporate updates.
Ticker impact
Regeneron reported Q2 2026 results with 17% revenue growth to $4.291B and highlighted major product sales gains plus Sanofi balance repayment.
Likely supportive near-term bias as investors price in stronger earnings power and clearer collaboration economics, though GAAP income declined year over year.
The 8-K includes specific quarterly financial figures, product net sales changes, and a concrete corporate financial event (full repayment of Sanofi Development Balance) tied to future profit recognition starting in Q3.
Market effects
Reinforces demand momentum in Regeneron’s key ophthalmology and immunology franchises (EYLEA HD, Dupixent) and supports sentiment for large-cap pharma earnings quality.
Limited direct regional spillover beyond US-listed pharma sentiment.
Global product sales growth and FDA/EMA regulatory progress can influence broader biotech/pharma risk appetite.
Counterpoint
GAAP net income and GAAP EPS declined year over year, and several pipeline updates include a Phase 3 primary endpoint miss for fianlimab, which could temper enthusiasm.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
NASDAQ-listed biotech/pharma issuer filing Q2 2026 results and business update.
- partnerSanofi
Collaboration counterparty; Regeneron states the Sanofi Development Balance was fully repaid by end of Q2 2026.
- regulatorFDA
Approved Dupixent expansion and EYLEA HD dosing interval extension; will review cemdisiran NDA under priority review.
- regulatorEMA
Accepted for review Otarmeni MAA under accelerated assessment and cemdisiran regulatory submissions for gMG.
